Aldeyra Therapeutics Announces 2024 Annual Meeting of Stockholders

Ticker: ALDX · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1341235

Sentiment: neutral

Topics: Aldeyra Therapeutics, Annual Meeting, Proxy Statement, DEF 14A, Stockholder Vote

TL;DR

<b>Aldeyra Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 4, 2024, encouraging prompt voting by all shareholders.</b>

AI Summary

Aldeyra Therapeutics, Inc. (ALDX) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. The 2024 Annual Meeting of Stockholders for Aldeyra Therapeutics, Inc. will be held on June 4, 2024. The meeting will take place at 8:00 a.m. local time at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP in Boston, Massachusetts. Stockholders are encouraged to vote via the Internet, telephone, or by mailing a proxy card. The proxy materials include the company's annual report on Form 10-K for the year ended December 31, 2023. Todd C. Brady, M.D., Ph.D., CEO, President, and Director, signed the notice.

Why It Matters

For investors and stakeholders tracking Aldeyra Therapeutics, Inc., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and voting procedures for the upcoming annual meeting, which is a standard corporate governance requirement. The meeting will cover essential business, including the election of directors, and provides an opportunity for shareholders to engage with the company's leadership and review its annual performance.

Risk Assessment

Risk Level: low — Aldeyra Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational news, indicating a low level of immediate risk or opportunity.

Analyst Insight

Review the proxy materials and annual report to understand the company's strategic direction, director nominees, and financial performance for 2023 before the June 4th meeting.

Key Numbers

Key Players & Entities

FAQ

When did Aldeyra Therapeutics, Inc. file this DEF 14A?

Aldeyra Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Aldeyra Therapeutics, Inc. (ALDX).

Where can I read the original DEF 14A filing from Aldeyra Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Aldeyra Therapeutics, Inc..

What are the key takeaways from Aldeyra Therapeutics, Inc.'s DEF 14A?

Aldeyra Therapeutics, Inc. filed this DEF 14A on April 22, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Aldeyra Therapeutics, Inc. will be held on June 4, 2024.. The meeting will take place at 8:00 a.m. local time at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP in Boston, Massachusetts.. Stockholders are encouraged to vote via the Internet, telephone, or by mailing a proxy card..

Is Aldeyra Therapeutics, Inc. a risky investment based on this filing?

Based on this DEF 14A, Aldeyra Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational news, indicating a low level of immediate risk or opportunity.

What should investors do after reading Aldeyra Therapeutics, Inc.'s DEF 14A?

Review the proxy materials and annual report to understand the company's strategic direction, director nominees, and financial performance for 2023 before the June 4th meeting. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement filed with the SEC. (This filing provides detailed information about the company's annual meeting, director nominations, and voting matters.)
Proxy Card
A document authorizing a designated person to vote shares on behalf of the shareholder. (Essential for shareholders who cannot attend the annual meeting but wish to cast their vote.)

Filing Stats: 4,800 words · 19 min read · ~16 pages · Grade level 13.4 · Accepted 2024-04-22 16:11:57

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 26 Summary Compensation Table 26 Narrative Explanation of Certain Aspects of the Summary Compensation Table 26 Severance and Change in Control Benefits 27 Employee Benefits and Perquisites 29 Stockholder Engagement 29 Clawback Policy 30 Restrictions on Trading 30 Outstanding Equity Awards at Fiscal 2023 Year-End 31

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 36 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 38 AUDIT COMMITTEE REPORT 39 OTHER MATTERS 40 -i- Table of Contents ALDEYRA THERAPEUTICS, INC. 131 Hartwell Avenue, Suite 320 Lexington, Massachusetts 02421 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS This proxy statement is furnished in connection with solicitation of proxies by our Board of Directors for use at the 2024 Annual Meeting of Stockholders (the Annual Meeting) to be held at 8:00 a.m. local time on Tuesday, June 4, 2024, and any postponements or adjournments thereof. The Annual Meeting will be held at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, One Marina Park Drive, Suite 900, Boston, Massachusetts 02210. Beginning on or about April 22, 2024, we mailed to our stockholders a Notice of Internet Availability of Proxy Materials (the Notice) containing instructions on how to access our proxy materials. As used in this proxy statement, the terms Aldeyra, the Company, we, us, and our mean Aldeyra Therapeutics, Inc. unless the context indicates otherwise. QUESTIONS AND ANSWERS ABOUT PROCEDURAL MATTERS Annual Meeting Q: Why am I receiving these proxy materials? A: Our Board of Directors is providing these proxy materials to you in connection with the solicitation of proxies for use at the Annual Meeting to be held on Tuesday, June 4, 2024 at 8:00 a.m. local time, and at any adjournment or postponement thereof, for the purpose of considering and acting upon the matters set forth herein. We intend to begin mailing these proxy materials on or about April 22, 2024 to all stockholders of record entitled to vote at the Annual Meeting. This proxy statement includes information that we are required to provide to you under Securities and Exchange Commission (the SEC) rules and that is designed to assist you in voting your shares. Q: What is included in the proxy mate

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing